---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-032815"
form_type: "8-K"
ticker: "SGMO"
cik: "0001001233"
company_name: "SANGAMO THERAPEUTICS, INC"
filed_at: "2024-07-24T23:59:59+00:00"
generated_at: "2026-05-31T16:36:10.374305+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Sangamo Phase 3 hemophilia A gene therapy meets primary endpoint with superiority over prophylaxis

## Summary
- AFFINE trial achieved superiority on total ABR (1.24 vs 4.73, p=0.0040) compared to FVIII prophylaxis.
- 84% of participants maintained FVIII activity >5% at 15 months; mean treated ABR reduced 98.3% (0.07 vs 4.08, p<0.0001).
- Sangamo eligible for up to $220M in regulatory/commercial milestones plus 14%-20% royalties on sales.
- One participant (1.3%) returned to prophylaxis; treatment generally well tolerated with transient elevated FVIII in 49.3%.
- Pfizer to discuss data with regulatory authorities; Sangamo's first potential commercial medicine.

## SEC filing metadata
- accession: 0001628280-24-032815
- form_type: 8-K
- ticker: SGMO
- cik: 0001001233
- company_name: SANGAMO THERAPEUTICS, INC
- filed_at: 2024-07-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001233/000162828024032815/0001628280-24-032815-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001233/000162828024032815/sgmo-20240724.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-032815
- JSON: https://secwatch.observer/filing/0001628280-24-032815.json
- Plain text: https://secwatch.observer/filing/0001628280-24-032815.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.